RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.
RCKT - Rocket Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$5.00
DETAILS
HIGH:
$5.00
LOW:
$5.00
MEDIAN:
$5.00
CONSENSUS:
$5.00
UPSIDE:
68.92%
Stock News
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the first quarter ended March 31, 2026. “During the first quarter, we continued advancing our cardiovascular gene therapy portfolio, including reinitiating dosing in the initial three-patient cohort of our p.
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strengthened financial position following the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). Rocket has entered into a definitive agreement to sell its PRV for $180 million. The PRV was awarded following the U.S. Food and Drug Adm.
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.
Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT)
Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Rocket Pharmaceuticals (NASDAQ: RCKT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends. Profitability This table compares Foghorn Therapeutics and
Rocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 Transcript
Rocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 Transcript
Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI
Rocket Pharmaceuticals (NASDAQ:RCKT) announced that the US Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI (marnetegragene autotemcel), the company's gene therapy for children with severe leukocyte adhesion deficiency-I (LAD-I) caused by biallelic variants in ITGB2. The therapy is intended for patients without an available human leukocyte antigen-matched sibling donor for allogeneic stem cell transplant.
Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder
Rocket Pharmaceuticals shares jumped 10% on Friday before the bell after the U.S. Food and Drug Administration approved its gene therapy for a rare and often fatal immune disorder in children, marking the first regulatory green light for a treatment of the condition.
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI™ (marnetegragene autotemcel), an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients with severe leukocyte adhesion defici.
Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI
Rocket Pharmaceuticals (NASDAQ:RCKT) announced that the US Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI (marnetegragene...
Rocket Pharmaceuticals, Inc. (RCKT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Rocket Pharmaceuticals, Inc. (RCKT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
Rocket Pharmaceuticals reports narrower-than-estimated Q4 loss. The company provides key updates on its pipeline candidates.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of “Hold” from Analysts
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) has been given an average recommendation of "Hold" by the seventeen research firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the fourth quarter and year ended December 31, 2025. “In 2025, we strengthened Rocket's leadership in cardiovascular gene therapy, supported by more than five years of clinical experience in Danon disease and cont.
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference and Leerink Partners Global Healthcare Conference in Boston and Miami, respectively. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat and manag.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Recommendation of “Hold” from Brokerages
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) have received a consensus rating of "Hold" from the seventeen analysts that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and eight have issued a buy recommendation
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Crosses Above Fifty Day Moving Average – Here’s Why
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report)'s stock price passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $3.43 and traded as high as $3.89. Rocket Pharmaceuticals shares last traded at $3.72, with a volume of 2,411,606 shares trading hands. Wall Street
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
3 cheap stocks that could turn $1,000 into $10,000
At the start of 2025, the stock market appeared unstable as most major assets were, seemingly, very overvalued. Despite this, there was no shortage of opportunities for savvy investors to find undervalued, cheap stocks that enabled them to turn a $1,000 into $10,000 of profit.
Price Targets
Rocket Pharmaceuticals price target lowered to $5 from $7 at Morgan Stanley
$5.00
(was $3.89)
Morgan Stanley
Rocket Pharmaceuticals price target lowered to $7 from $9 at Leerink
$7.00
(was $3.26)
Leerink Partners
Goldman downgrades Rocket to Sell on 'surprising and concerning' update
$2.00
(was $2.48)
Richard Law
·
Goldman Sachs
These Analysts Slash Their Forecasts On Rocket Pharmaceuticals
$2.50
(was $2.48)
Andrew Tsai
·
Jefferies
Rocket Pharmaceuticals initiated with an Outperform at Wedbush
$32.00
(was $12.03)
Yun Zhong
·
Wedbush
Rocket Pharmaceuticals (RCKT) PT Raised to $39 at Canaccord Genuity
$39.00
(was $17.09)
Whitney Ijem
·
Canaccord Genuity
Canaccord Genuity Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT)
$38.00
(was $21.80)
Whitney Ijem
·
Canaccord Genuity
Morgan Stanley on Rocket Pharmaceuticals (RCKT): 'we are encouraged by rapid enrollment'
$45.00
(was $21.18)
Michael E Ulz
·
Morgan Stanley
Goldman Sachs Starts Rocket Pharmaceuticals (RCKT) at Neutral, 'Four Potential Launches in Next 2Y but DD Oppy May be Overstated'
$39.00
(was $26.72)
Richard Law
·
Goldman Sachs
Raymond James Maintains Outperform on Rocket Pharmaceuticals, Raises Price Target to $34
$34.00
(was $15.96)
Raymond James
Raymond James Maintains Outperform on Rocket Pharmaceuticals, Raises Price Target to $24
$24.00
(was $15.17)
Raymond James
Rocket Pharmaceuticals (RCKT) PT Lowered to $69 at UBS
$69.00
(was $30.80)
Esther Rajavelu
·
UBS